文献速递糖尿病

入院时空腹血糖是既往未诊断糖尿病的COVID-19患者28天死亡率的独立预测因素:一项多中心回顾性研究

Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study.
PubMed 文献 · Diabetologia · 2020-07-10

该多中心回顾性研究纳入2020年1月24日至2月10日武汉两家医院605例既往未诊断糖尿病的COVID-19患者,分析入院空腹血糖(FBG)与28天死亡率的关系。多变量Cox回归显示FBG≥7.0 mmol/l是28天死亡的独立预测因素(HR 2.30,95%CI 1.49-3.55),且FBG≥7.0 mmol/l和6.1-6.9 mmol/l组28天院内并发症OR分别为3.99和2.61。作者认为血糖检测和控制对所有COVID-19患者均重要。

要点

  • FBG≥7.0 mmol/l是既往未诊断糖尿病的COVID-19患者28天死亡的独立预测因素(HR 2.30,95%CI 1.49-3.55)。
  • FBG≥7.0 mmol/l组28天院内并发症OR为3.99(95%CI 2.71-5.88),6.1-6.9 mmol/l组OR为2.61(95%CI 1.64-4.41)。
  • 年龄、男性、CRB-65评分1-2分和3-4分也是28天死亡的独立预测因素。

核心结论

  • 入院时FBG≥7.0 mmol/l是既往未诊断糖尿病的COVID-19患者28天死亡的独立预测因素。
  • 作者认为血糖检测和控制对所有COVID-19患者均重要,即使无既往糖尿病,因为大多数COVID-19患者易出现糖代谢紊乱。

研究设计与样本

  • 多中心回顾性研究,纳入2020年1月24日至2月10日武汉两家医院所有连续且具有明确28天结局和入院FBG测量的COVID-19患者。
  • 共纳入605例COVID-19患者,其中114例在医院死亡。

主要发现

  • 多变量Cox回归分析显示,年龄(HR 1.02,95%CI 1.00-1.04)、男性(HR 1.75,95%CI 1.17-2.60)、CRB-65评分1-2分(HR 2.68,95%CI 1.56-4.59)、CRB-65评分3-4分(HR 5.25,95%CI 2.05-13.43)和FBG≥7.0 mmol/l(HR 2.30,95%CI 1.49-3.55)是28天死亡的独立预测因素。
  • FBG≥7.0 mmol/l和6.1-6.9 mmol/l组相比FBG<6.1 mmol/l组,28天院内并发症的OR分别为3.99(95%CI 2.71-5.88)和2.61(95%CI 1.64-4.41)。

关键数值与推荐

  • CRB-65评分基于四项指标:意识模糊、呼吸频率>30次/分、收缩压≤90 mmHg或舒张压≤60 mmHg、年龄≥65岁。
  • FBG≥7.0 mmol/l定义为高血糖组,6.1-6.9 mmol/l为中间组,<6.1 mmol/l为参照组。

临床怎么用

  • 作者认为血糖检测和控制对所有COVID-19患者均重要,即使无既往糖尿病。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Hyperglycaemia is associated with an elevated risk of mortality in community-acquired pneumonia, stroke, acute myocardial infarction, trauma and surgery, among other conditions. In this study, we examined the relationship between fasting blood glucose (FBG) and 28-day mortality in coronavirus disease 2019 (COVID-19) patients not previously diagnosed as having diabetes. METHODS: We conducted a retrospective study involving all consecutive COVID-19 patients with a definitive 28-day outcome and FBG measurement at admission from 24 January 2020 to 10 February 2020 in two hospitals based in Wuhan, China. Demographic and clinical data, 28-day outcomes, in-hospital complications and CRB-65 scores of COVID-19 patients in the two hospitals were analysed. CRB-65 is an effective measure for assessing the severity of pneumonia and is based on four indicators, i.e. confusion, respiratory rate (>30/min), systolic blood pressure (≤90 mmHg) or diastolic blood pressure (≤60 mmHg), and age (≥65 years). RESULTS: Six hundred and five COVID-19 patients were enrolled, including 114 who died in hospital. Multivariable Cox regression analysis showed that age (HR 1.02 [95% CI 1.00, 1.04]), male sex (HR 1.75 [95% CI 1.17, 2.60]), CRB-65 score 1-2 (HR 2.68 [95% CI 1.56, 4.59]), CRB-65 score 3-4 (HR 5.25 [95% CI 2.05, 13.43]) and FBG ≥7.0 mmol/l (HR 2.30 [95% CI 1.49, 3.55]) were independent predictors for 28-day mortality. The OR for 28-day in-hospital complications in those with FBG ≥7.0 mmol/l and 6.1-6.9 mmol/l vs <6.1 mmol/l was 3.99 (95% CI 2.71, 5.88) or 2.61 (95% CI 1.64, 4.41), respectively. CONCLUSIONS/INTERPRETATION: FBG ≥7.0 mmol/l at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes. Glycaemic testing and control are important to all COVID-19 patients even where they have no pre-existing diabetes, as most COVID-19 patients are prone to glucose metabolic disorders. Graphical abstract.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Wang S, Ma P, Zhang S, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia. 2020. PMID: 32647915. doi:10.1007/s00125-020-05209-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。